Does Celexa Affect Sex Drive? What the Citalopram Studies Actually Show

Does Celexa Affect Sex Drive? What the Citalopram Studies Actually Show

Celexa and sex drive have a documented relationship, and the studies split it in two. In 1,473 people in outpatient care treated openly with Celexa (citalopram) for up to 14 weeks, 799 (54%) reported decreased libido and 525 (36%) reported difficulty finishing. In 48 healthy men given citalopram, fluoxetine or placebo for 4 weeks, citalopram delayed finishing and left the desire items alone. In 308 people in primary care on sertraline or citalopram for 6 months, desire scores improved overall, while 11.8% of women and 16.7% of men with no problem at the start reported decreased desire by week 24.

Before you read on

Celexa is a prescription medicine that is doing work you cannot feel. Do not stop it, lower it or switch it without your prescriber. Nothing here is medical advice or a reason to alter your treatment plan.

Key takeaways
  • In 1,473 people in outpatient care on open citalopram for up to 14 weeks, 799 (54%) reported decreased libido, 525 (36%) difficulty finishing, and 211 of 574 men (37%) erection problems. Self-report, no placebo arm, and a genetic analysis restricted to Caucasian participants.
  • In 48 healthy men over 4 weeks, citalopram delayed finishing against placebo, every questionnaire item score fell except the desire items, and machine-measured erection function showed no change from placebo.
  • In 308 people in primary care over 6 months, desire improved in women and men. Among those with no problem at the start, 11.8% of women and 16.7% of men reported decreased desire by week 24, and 25% of men reported a finishing-phase problem. Sertraline and citalopram did not differ.
  • In 357 people randomized for 24 weeks, trouble finishing was reported by 39% of sexually active women on citalopram against 5.9% on reboxetine. No placebo arm, and dropouts ran 91 on reboxetine against 54 on citalopram.
  • In 119 people with hard-to-treat depression on citalopram or paroxetine, direct questioning found a sexual problem in 41% against 6% by spontaneous report. The two drugs did not differ, and the problems tied to nothing in dose, blood level or time on the drug.
54%
of people on citalopram reported decreased libido, 799 of 1,473, in Perlis 2009.
39%
of sexually active women on citalopram reported trouble finishing at 24 weeks, against 5.9% on reboxetine, Langworth 2006.
11.8%
of women with no sexual problem at the start reported decreased desire after 24 weeks, against 16.7% of men, Ekselius 2001.

Figures from Perlis et al. 2009 (PMID 19295509), Langworth et al. 2006 (PMID 16633139) and Ekselius and von Knorring 2001 (PMID 11270911). The first is an open-treatment cohort; the other two are randomized comparisons without a placebo arm.

Is it the Celexa, or is it me?

Type the question into a search bar and the results are horror stories with no numbers in them. Depression and anxiety flatten desire before any pill enters the picture, so when Celexa and sex drive arrive in the same sentence, the causes come tangled. No quiz on the internet pulls them apart.

Ekselius and von Knorring (2001) show that tangle inside one dataset. In 308 people in primary care treated for a depressive episode, desire scores rose over 6 months as the depression lifted. In the subgroup who reported no sexual problem at the start, 11.8% of women and 16.7% of men reported decreased desire by week 24. Both facts sit in the same group of people, since the illness improving brings wanting back and a counted minority pick up a new problem on the way.

This page keeps three stacks apart. The counted rates in people who were ill when they started. The healthy-men trial, where depression has no seat at the table. And the studies on what moves those numbers afterward. If low mood is doing most of the work, depression and low libido is the closer read. For the wider drug picture, see what helps an SSRI libido drop and what doctors do not say about antidepressants and libido.

The counted rates on citalopram

Perlis and colleagues (2009) worked from STAR*D, a multicenter prospective effectiveness trial in people with nonpsychotic major depressive disorder in outpatient care. 1,473 Caucasian participants with DNA samples and adverse-effect measures took citalopram openly for up to 14 weeks, and reported on the trial's self-rated side-effect inventory. 799 of 1,473 (54%) reported decreased libido. 525 (36%) reported difficulty finishing. Of 574 men, 211 (37%) reported erection problems.

The same paper ran a genetic test on those reports. Polymorphisms in glutamatergic genes lined up with particular items: GRIA3 and GRIK2 with decreased libido, GRIA1 with difficulty finishing, GRIN3A with trouble with erections, each at permuted p values below 0.05 across the experiment. The signal held after adjustment for baseline clinical and sociodemographic differences, and in the subgroup whose events were known to have begun after the drug. The authors call those analyses hypothesis-generating, and the cohort is Caucasian only. Add self-report and an open arm with no placebo, and you have a strong counting study that cannot tell you who lands in the 54%.

What 1,473 people on citalopram reported

Share reporting each problem on the self-rated side-effect inventory during up to 14 weeks of open citalopram treatment, STAR*D cohort.

Three reported problems in 1,473 people on citalopram Bars from the STAR*D citalopram cohort of Perlis 2009: decreased libido 54% (799 of 1,473), difficulty finishing 36% (525 of 1,473), erection problems 37% (211 of 574 men). Self-report, open-label, no placebo arm. Decreased libido 54% 799 of 1,473 Difficulty finishing 36% 525 of 1,473 Erection problems 37% 211 of 574 men 0% 10% 20% 30% 40% 50% 60%

Source: Perlis RH et al. 2009 (PMID 19295509). Open treatment, self-report, no placebo arm; the cohort was restricted to Caucasian participants for the genetic analysis.

Other counts point the same way. Montejo and colleagues (2001) interviewed 1,022 people in outpatient care who had normal sexual function before starting an antidepressant alone: 59.1% reported a problem overall, and citalopram carried 72.7% (48 of 66), the highest of the ten drugs in that study, with men at 62.4% and women at 56.9%. Sertraline sat at 62.9% and fluoxetine at 57.7%, and the Zoloft and Prozac pages chart those rows. Citalopram's close relative is a separate molecule: Lexapro and sex drive covers escitalopram on its own page, and Zoloft and sex drive covers sertraline.

Serretti and Chiesa (2009) pooled studies that asked directly with specific questionnaires, in people with no prior sexual problem, and put citalopram third in a decreasing order of impact, with rates across the implicated drugs running 25.8% to 80.3% of people. Scales differ across those studies, open-label work was included, and the authors say that spread could reduce the significance of the findings. Landén and colleagues (2005) explain why clinic numbers vary so much: asked directly, 41% of 119 people on citalopram or paroxetine reported a sexual problem; volunteering it themselves, 6%.

The healthy-men trial, where depression cannot explain it

Madeo and colleagues (2008) took depression out of the picture. 48 healthy men with a mean age of 29.5 were randomized to placebo (16), fluoxetine 20 milligrams a day (16), or citalopram 20 milligrams a day for the first week then 40 milligrams a day for the next 3 weeks (16). Four weeks total.

Erection parameters measured by RigiScan during an erection test showed no difference from placebo on either drug. Finishing time took longer on both drugs against placebo, and that delay held on citalopram alone. On the IIEF-15 every item score fell except the desire items, and the fall in scores showed up in the statistics only on citalopram. The men's own rating of erection quality did fall on citalopram. The authors read that as delayed finishing being perceived as a problem, since the machine-measured erection was unchanged.

Two smaller studies sit beside it. Bilderbeck and colleagues (2014) gave 44 healthy adults in romantic relationships 8 days of citalopram (21 people) or placebo (23). The citalopram group rated the physical and intimate side of their own relationships as less important, and rated mutual trust higher. The authors call this preliminary, the outcomes are judgements about relationships, and the abstract carries no numbers beyond group sizes. Jensen and colleagues (2024) followed 26 unmedicated men starting escitalopram, a different drug: the men who reported sexual side effects had lower pretreatment estradiol and testosterone, with low estradiol tied to erection and finishing-phase problems at p = 0.039.

Say it plainly. In men with no depression, citalopram moved finishing and left wanting alone. If your own picture is a flat appetite, low libido in men covers the wider ground.

Women, specifically

Langworth and colleagues (2006) randomized 357 people with major depressive disorder to reboxetine 8 to 10 milligrams a day or citalopram 20 to 40 milligrams a day for 24 weeks, double-blind, with no placebo arm. At week 24, 39% of sexually active women on citalopram reported trouble finishing against 5.9% of those on reboxetine. Depression scores improved on both drugs. Sexual problems were the most common side effect on citalopram, dry mouth on reboxetine. Dropouts ran 91 on reboxetine against 54 on citalopram, which the authors attribute to a non-titrated 8 milligram start.

Ekselius and von Knorring (2001) found a mixed picture in women. Desire scores and the mean total score rose across the 6 months of treatment, which is what you would expect as depression lifts. In the subgroup of women who started with no sexual problem, 11.8% reported decreased desire at week 24 and 14.3% reported trouble finishing.

Abbasinazari and colleagues (2018) compared fluoxetine 20 milligrams a day with citalopram 20 milligrams a day in women over 1 month, with 23 completers of 39. Female Sexual Function Index scores were 22.8 (SD 7.8) on fluoxetine and 22.5 (SD 4.8) on citalopram, no difference at p = 0.89. Oxytocin ran lower on fluoxetine at p = 0.05. Pilot size, one month, no placebo arm.

Preeti and colleagues (2018) followed 209 people on five antidepressants for 6 weeks: a problem in any domain went from 29% at baseline to 41% by week 6, desire improved, and the finishing item in women worsened. Citalopram was not among the drugs studied, and escitalopram is a separate molecule. For the wider picture, read low libido in women.

Does it wear off, and what moves it

Landén and colleagues (2005) found nothing that predicts a fade. In 119 people on citalopram or paroxetine, sexual problems showed no link with age, dose, plasma level, how long someone had been on the drug, or any depression measure. They linked to the length of the depressive episode. The authors read that missing link with duration as support for the idea that SSRI side effects do not fade over time.

Switching is a prescriber's move, and the data on it cut two ways. Calabrese and colleagues (2003) switched 55 people intolerant of fluoxetine to citalopram 20 milligrams a day, titrated to 40 milligrams: decreased libido came back in only 5 of 28 cases (18%), and 95% completed. Open-label, no comparator, side effects captured by spontaneous report, which undercounts. In Katz and colleagues (2012), 727 people who failed first-step citalopram moved to a second drug: distressing adverse events went from 70.7% at step 1 to 86.1% at step 2, a sexual event was likelier when the same event had happened first (risk ratio 2.75, 95% CI 2.29 to 3.29), and urinary and reproductive events did the same at 3.39 (95% CI 2.41 to 4.78). Duloxetine works on two messengers where citalopram works on one, which is why the Cymbalta and sex drive page reads its trials separately.

Reporting databases describe how often clinicians file a report. They cannot give you your odds. In VigiBase, paroxetine carried the highest sexual-problem signal of six SSRIs studied, and no citalopram figure for that domain appears in the abstract. In FAERS, the broad sexual-problem reporting odds ratio for citalopram was 15.09 (95% CI 12.98 to 17.54), with the authors stating that the variation reflects reporting differences and not comparative risk, in a dataset of male reports only. Greil and colleagues (2001) described five people who noticed a strange increase in libido during remission, on an SSRI, a dose change or a stop, framed by the authors as a possible switch toward partly manic symptoms. Five solicited cases give no rate at all.

Dose, timing, switching, adding: every lever on that list belongs to your prescriber, and stopping Celexa on your own is the one move nobody in these studies made for you. Bring the numbers and the sentence describing your own change. If the question is what happens after a stop, libido after stopping antidepressants is the next read.

What has been counted, in order

Seven studies measured sexual function on citalopram, the drug sold as Celexa, between 2001 and 2009, and they do not all measure the same thing. Some asked people being treated for depression. One gave the drug to healthy men. One compared it head to head with a different antidepressant. Reading them in date order shows how the picture built: a desire hit counted in outpatient care, a desire result that improved as mood improved, a finishing delay pinned on the drug in men with no depression at all, and one 1473-person cohort that counted every item at once. The design decides what each number can say.

Seven looks at citalopram and sex

2001 Ekselius

308 people in primary care, 6 months on sertraline or citalopram. Desire improved overall, and 11.8% of women and 16.7% of men with no problem at the start reported one by week 24.

2001 Montejo

1022 people in outpatient care, any sexual problem counted by questionnaire. Citalopram 72.7%.

2003 Calabrese

55 people switched off fluoxetine. Decreased libido came back in 5 of 28 cases.

2005 Landen

119 people with hard-to-treat depression. A problem in 41% when asked directly, 6% reported on their own.

2006 Langworth

357 people randomized for 24 weeks. Trouble finishing in 39% of sexually active women on citalopram against 5.9% on reboxetine.

2008 Madeo

48 healthy men, 4 weeks against placebo. Finishing delayed on citalopram, desire items untouched.

2009 Perlis

1473 people treated openly for up to 14 weeks. Decreased libido in 54%, difficulty finishing in 36%.

Built from PMID 11270911, 11229449, 12755660, 15669895, 16633139, 18410297 and 19295509. Open-label designs sit in this list, so read every figure with its design attached.

Celexa in the studies: what each measured, and what it says about desire.
Study Design Who Finding What it says about desire
Perlis 2009 Open-label cohort from a multicenter effectiveness trial 1473 people with depression in outpatient care 54% decreased libido, 36% difficulty finishing, 37% of men with erection problems Self-report in an open arm with no placebo group
Madeo 2008 Randomized, placebo-controlled, double-blind 48 healthy men Finishing delayed on citalopram; desire items unchanged Small, 4 weeks, men with no depression
Ekselius 2001 Randomized double-blind, no placebo arm 308 people in primary care Desire improved overall over 6 months; 11.8% of women and 16.7% of men gained a desire problem Two SSRIs, no significant difference between them
Langworth 2006 Randomized double-blind, 24 weeks 357 people with depression Trouble finishing 39% of sexually active women against 5.9% on reboxetine Many reboxetine dropouts, 91 against 54
Landen 2005 Add-on trial subset, 4 weeks 119 people on citalopram or paroxetine 41% found by direct questioning against 6% spontaneous report Not tied to dose or how long the drug was taken
Montejo 2001 Open-label, multicenter, prospective 1022 people in outpatient care Citalopram 72.7% for any sexual problem Counted by questionnaire, no placebo arm
Clayton 2015 Post hoc analysis of a randomized blinded trial People with depression, citalopram 40 milligrams as the active control Scores rose in every group, more in people who responded No inferential statistics were run
Serretti 2009 Meta-analysis of drugs measured by direct questioning People with no prior sexual problem, across ten antidepressants that beat placebo Rates from 25.8% to 80.3%, citalopram third in the ranking No citalopram-only rate printed in the abstract

What actually helps, graded honestly

The first lever is free, and it is the biggest one in these numbers. Landen and colleagues (2005) asked 119 people directly about sexual function and found a problem in 41%; only 6% had mentioned one on their own, p under 0.001. Their conclusion is that open-ended questions miss the thing entirely. If you have never said the word desire out loud in a consultation, that conversation is step one, and what helps an SSRI libido drop walks through what to ask for.

The second lever is the depression itself. Ekselius and von Knorring (2001) followed 308 people in primary care for 6 months and found sexual desire significantly improved in women and improved in men as mood lifted. Landen found the problems tracked the length of the depressive episode. Part of your number belongs to the illness, and treating the illness moves it.

Waiting is the weakest option on this list. Landen found no link between the problem and dose, plasma level, or how long the SSRI had been taken, a pattern the authors read as side effects that do not fade with time.

Switching has counted outcomes and its own costs. Langworth and colleagues (2006) reported sexual problems as the commonest issue on citalopram against dry mouth on reboxetine, alongside 91 dropouts on reboxetine against 54 on citalopram. Calabrese and colleagues (2003) switched 55 people off fluoxetine and saw decreased libido return in 5 of 28 cases. Katz and colleagues (2012) counted distressing adverse events in 626 of 727 people, 86.1%, at the second step. All of it is a prescriber's call. Buspirone and sex drive and Wellbutrin and sex drive cover the add-on options people ask about most.

What to bring to your doctor

Bring specifics. Every study above found its numbers by asking precise questions, and a precise answer gets a more useful reply than a general complaint about libido. Five things are worth writing down before the appointment, in your own words, with dates where you have them.

  1. Which items changed. Name desire, finishing, and erections separately. Perlis and colleagues (2009) counted them as three numbers in 1473 people, 54%, 36% and 37% of men, so one of them can be handled on its own.
  2. When it started, relative to the dose. Say what changed and when. Landen found no link to dose, plasma level or time on the drug, so a dose change is a weak bet and worth hearing said out loud.
  3. The depression picture. How long this episode has run, since Landen found problems tracking episode length and Ekselius found desire rising as mood lifted over 6 months.
  4. Whether a switch question fits, asked as a question. Langworth, Calabrese and Katz all counted what happens after a change, and each carries costs. Bring your own history of side effects with it.
  5. The supplement question, bottle in hand. Say the name, show the label, and let your prescriber read the ingredient list.

The everyday levers, and where a botanical fits

Start with who this section is not for. Blood-pressure medication and heart, kidney or lung conditions are common, and they are exactly what NUUD's own label names: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. If that sentence describes you, it is the answer here, and the rest of this section is not for you.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

  • Sleep, in quantity and quality, since depression, anxiety and sleep medication all feed broken sleep, and broken sleep feeds flat wanting. Sleep, libido and testosterone covers that.
  • Movement you can keep up, on the days your energy allows it. Exercise and libido covers the wider picture.
  • Your mood and your anxiety, named out loud in the consultation and taken as seriously as the side effects are.
  • Time with a partner, or on your own, with nothing expected at the end.
  • A botanical supplement, if you want one, as the smallest lever on this list.

NUUD is a botanical supplement built around desire in general. It does nothing for Celexa (citalopram), for citalopram's side effects, for serotonin, or for depression and anxiety, and no interaction study exists between this formula and citalopram. It has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your doctor decides the rest. If your doctor has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Two answers online do you no good. The first is the shrug, the one that says everyone on an SSRI loses their drive and you should get used to it. The second is the forum certainty that Celexa has ended your sex life for good. Neither matches what was counted.

Here are those numbers in plain words. In 1473 people being treated for depression, 54% reported decreased libido on a questionnaire. In 48 healthy men taking the same drug for 4 weeks, the desire items did not move at all. In 308 people followed for 6 months in primary care, 11.8% of women and 16.7% of men developed low desire, and desire improved overall in that same group as mood lifted. The illness flattens wanting and the drug flattens wanting, and the two arrive together. Wanting is not gone from you. You want to want it again, and that sentence describes a target, a conversation with your prescriber, and a set of levers worth working through in order.

Keep reading

Frequently asked questions

Does Celexa lower sex drive?
Yes, in a counted share of people being treated for depression. In 1473 people treated openly with citalopram for up to 14 weeks, 799 (54%) reported decreased libido. The picture splits in two. In 48 healthy men taking citalopram for 4 weeks against placebo, the desire items on the questionnaire did not change. In 308 people in primary care followed for 6 months, desire improved overall, while 11.8% of women and 16.7% of men with no problem at the start reported decreased desire by week 24.

Is Celexa worse than other SSRIs for sexual side effects?
Nobody has settled it. In a study of 1022 people in outpatient care, citalopram carried 72.7% for any sexual problem, the highest of the ten antidepressants counted there. A meta-analysis ranked citalopram third among the drugs that beat placebo, with rates from 25.8% to 80.3%, and printed no citalopram-only rate. Two head-to-head comparisons found no significant difference: citalopram against sertraline over 6 months, and citalopram against paroxetine over 4 weeks.

Does Celexa delay finishing?
That is the item the cleanest trial pins on the drug. In 48 healthy men randomized against placebo for 4 weeks, finishing time was delayed, and the delay reached significance only with citalopram. In a 24-week randomized comparison, 39% of sexually active women on citalopram reported trouble finishing against 5.9% on reboxetine. In the 308-person primary care study, 25% of the men with no problem at the start reported a finishing-phase problem by week 24.

Do Celexa sexual side effects go away?
Some do, and the drug is only part of the reason. Landen and colleagues (2005) found the problems tracked the length of the depressive episode, with no link to how long the SSRI had been taken, which the authors read as side effects that do not fade with time. Over 6 months in primary care, desire improved for most people as the depression lifted. After a switch off fluoxetine, decreased libido came back in 5 of 28 cases, so 18% kept the problem.

Can I take a botanical supplement with Celexa?
Ask your prescriber first, with the bottle in hand. NUUD's label says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. NUUD is a botanical supplement built around desire in general, and it does nothing for citalopram, for serotonin, or for depression and anxiety. No interaction studies exist between this formula and citalopram.

References

  1. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of clinical psychopharmacology. 2009;29(3):259-66. https://pubmed.ncbi.nlm.nih.gov/19440080/
  2. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(7):1819-28. https://pubmed.ncbi.nlm.nih.gov/19295509/
  3. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Journal of clinical psychopharmacology. 2006;26(2):121-7. https://pubmed.ncbi.nlm.nih.gov/16633139/
  4. Clayton AH, Gommoll C, Chen D, Nunez R, Mathews M. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. International clinical psychopharmacology. 2015;30(4):216-23. https://pubmed.ncbi.nlm.nih.gov/26039688/
  5. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. The Journal of clinical psychiatry. 2005;66(1):100-6. https://pubmed.ncbi.nlm.nih.gov/15669895/
  6. Abbasinazari M, Heidari-Kord M, Mazaheri-Meybodi A, Eshraghi A, Bayati N. Plasma Oxytocin Level and Sexual Dysfunction in Depressed Women Treated by Either Fluoxetine or Citalopram: a Pilot Clinical Trial. Iranian journal of pharmaceutical research : IJPR. 2018;17(1):408-414. https://pubmed.ncbi.nlm.nih.gov/29755571/
  7. Ekselius L, von Knorring L. Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care. Journal of clinical psychopharmacology. 2001;21(2):154-60. https://pubmed.ncbi.nlm.nih.gov/11270911/
  8. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of clinical psychiatry. 2001;62 Suppl 3:10-21. https://pubmed.ncbi.nlm.nih.gov/11229449/
  9. Madeo B, Bettica P, Milleri S, et al. The effects of citalopram and fluoxetine on sexual behavior in healthy men: evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebo-controlled, double-blind, double-dummy, parallel group study. The journal of sexual medicine. 2008;5(10):2431-41. https://pubmed.ncbi.nlm.nih.gov/18410297/
  10. Calabrese JR, Londborg PD, Shelton MD, Thase ME. Citalopram treatment of fluoxetine-intolerant depressed patients. The Journal of clinical psychiatry. 2003;64(5):562-7. https://pubmed.ncbi.nlm.nih.gov/12755660/
  11. Chan ACY. Comparative Real-World Safety Profiles of Six Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis. Cureus. 2025;17(12):e98677. https://pubmed.ncbi.nlm.nih.gov/41510438/
  12. Li S, Feng J, Zhang S. Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. Journal of affective disorders. 2026;402:121336. https://pubmed.ncbi.nlm.nih.gov/41662926/
  13. Preeti S, Jayaram SD, Chittaranjan A. Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. 2018;28(1):9-16. https://pubmed.ncbi.nlm.nih.gov/29588433/
  14. Bilderbeck AC, Wakeley J, Godlewska BR, et al. Preliminary evidence that sub-chronic citalopram triggers the re-evaluation of value in intimate partnerships. Social cognitive and affective neuroscience. 2014;9(9):1419-25. https://pubmed.ncbi.nlm.nih.gov/23996287/
  15. Katz AJ, Dusetzina SB, Farley JF, et al. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy. 2012;32(3):234-43. https://pubmed.ncbi.nlm.nih.gov/22392456/
  16. Shen M, He L, Chen P, et al. Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis. Sexual medicine. 2026;14(2):qfag008. https://pubmed.ncbi.nlm.nih.gov/41877765/
  17. Jensen KHR, Aarestrup MR, Larsen SV, et al. Psychoneuroendocrine profiles of unmedicated men with major depressive disorder and associations to treatment effects and sexual side-effects. Neuroscience applied. 2024;3:104050. https://pubmed.ncbi.nlm.nih.gov/40656082/
  18. Greil W, Horvath A, Sassim N, Erazo N, Grohmann R. Disinhibition of libido: an adverse effect of SSRI?. Journal of affective disorders. 2001;62(3):225-8. https://pubmed.ncbi.nlm.nih.gov/11223111/
  19. Clark SL, Adkins DE, Aberg K, et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychological medicine. 2012;42(6):1151-62. https://pubmed.ncbi.nlm.nih.gov/22041458/

This article is for general education and is not medical advice. Depression and anxiety disorders are medical conditions that only a licensed clinician can diagnose and manage. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing them or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change any medication without your doctor.

Back to blog